NASDAQ:KRTX - Nasdaq - US48576A1007 - Common Stock - Currency: USD
Hedge funds are shifting towards stability and value by favoring the health care sector over booming tech stocks.
Karuna Therapeutics (KRTX) experienced a temporary stock decline of 7.6%, but has since recovered to a 2% loss.
Karuna Therapeutics reports Q4 financial results, with a GAAP EPS of -$3.01, missing expectations by $0.29.
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.
Redburn Atlantic downgrades Bristol-Myers Squibb (BMY) due to headwinds against its products despite the company's recent buyout deals. Read more here.
Evaluate Vantage ranks Karuna Therapeutics'(KRTX) lead asset, KarXT, as this year's most anticipated drug ahead of Eli Lilly's (LLY) donanemab. Read more here.
Evaluate Vantage ranks Karuna Therapeutics' (KRTX) lead asset, KarXT, as this year's most anticipated drug ahead of Eli Lilly's (LLY) donanemab. Read more here.
Bristol Myers Squibb (BMY) successfully fought to acquire Karuna Therapeutics (KRTX) in a $14B deal, outmaneuvering another large pharma bidder. Read more here.
Mentions: BMY
Bristol Myers Squibb (BMY) reportedly expects to launch 16 new products by the end of the decade, but will be looking for smaller deals after its 2023 shopping
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain.
Bank of America downgrades Bristol-Myers Squibb (BMY) to Neutral due to concerns over upcoming patent expiries. Read more here.
Biotech M&A ended 2023 with a bang, but can investors expect the party to continue into 2024? And will the IPO market finally bounce back? Read more here.
The major indexes boast big annual gains with the Dow at record highs.